{"filings":[{"id":1113757,"accession_number":"0001079973-26-000855","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2026-06-17T21:28:41+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ProtoKinetix appoints new President, forms SightPath Biotech, patents valued at $253M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director McDonough resigned March 31; June 17: Jones, Lamp, Brunt appointed directors, Brunt as President.","Formed SightPath Biotech LLC for dry-eye drug PKX-001; patent valuation ~$253M per IQVIA & Benoit & Cote studies.","Late filings: 2025 10-K (Mar 31) and Q1 2026 10-Q (May 15); company still working to complete.","Repriced 61.19M options and 6M warrants from $0.028 to $0.01, extended expiry to Dec 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117884,"accession_number":"0001553350-25-000111","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProtoKinetix CEO updates on founder Clarence Smith's passing and AAGP molecule strategy","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Guzzetta acknowledges sudden passing of longtime leader Clarence Smith and commitment to his vision.","Company continues development of first-in-class synthetic glycopeptide AAGP (PKX-001) for cell protection and inflammation control.","Global patent portfolio covers US, Europe, UK, Asia; outreach to pharma firms for Type 1 Diabetes, cell therapy, dry-eye, and topical applications.","No financial or operational metrics provided; update is a stockholder letter with no specific milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117881,"accession_number":"0001079973-25-001802","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K/A","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProtoKinetix CEO Clarence Smith dies in accident; CFO Guzzetta named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President & CEO Clarence E. Smith died in a tragic accident on November 13, 2025.","Michael Guzzetta appointed Chairman, President, and CEO on November 16, 2025.","Guzzetta will also continue as CFO, Secretary, and Treasurer of the clinical-stage biotech.","This 8-K/A corrects the contact number in the prior filing and adds the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117883,"accession_number":"0001079973-25-001778","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ProtoKinetix CEO Clarence Smith dies in accident; CFO Guzzetta assumes all top roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Clarence E. Smith died Nov 13, 2025 in a tragic accident; served as CEO since 2015.","Sole remaining director Ed McDonough appointed Michael Guzzetta as Chairman, CEO, President on Nov 16.","Guzzetta continues as CFO, Secretary, Treasurer; his 2017 employment agreement unchanged.","ProtoKinetix is a clinical-stage biomedical company (OTC: PKTX) with no disclosed financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117882,"accession_number":"0001079973-25-001594","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"ProtoKinetix shareholders approve 20% increase in authorized common shares to 600M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment raising authorized shares from 500M to 600M; 222,125,724 votes in favor.","Consent solicitation closed October 6, 2025; holders of 57.1% of outstanding shares consented.","Record date was September 5, 2025, with 389,080,152 shares outstanding and entitled to vote.","Certificate of Amendment filed October 9, 2025, effective as of that date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312718,"accession_number":"0001079973-23-000152","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProtoKinetix issues 2M shares to CEO at $0.02/share in private placement raising $40K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,000,000 shares to President/CEO Clarence E. Smith at $0.02 per share for total proceeds of $40,000.","Private placement relied on exemption under Section 4(a)(2) and Rule 506(b); no commissions paid.","No solicitation was used; a Form D was filed separately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312717,"accession_number":"0001079973-23-000012","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"ProtoKinetix issues 1.85M shares to CEO in private placement at $0.02/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,850,000 shares of common stock to President and CEO Clarence E. Smith.","Price per share: $0.02; total proceeds: $37,000.","Offering exempt under Section 4(a)(2) and Rule 506(b); no commissions paid.","Form D to be filed within 15 days of December 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331228,"accession_number":"0001079973-22-001546","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"ProtoKinetix issues 2.52M shares to CEO at $0.025; reprices 93.5M options to $0.028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,520,000 shares to CEO Clarence Smith at $0.025/share in private placement, raising $63,000.","Board cancelled 93.54M options with above-market exercise prices and granted replacement options at $0.028, expiring Dec 6, 2028.","Replacement options: 45.61M to CEO & CFO, 7.5M to a director, 40.43M to three consultants.","Cancelled a consultant's warrant for 6M shares at $0.26; issued new warrant at $0.028 expiring Dec 12, 2028.","Total options outstanding under the 2017 Plan stand at 94,690,000 shares after these changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385122,"accession_number":"0001079973-22-000312","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"ProtoKinetix issues 1M units for $50k, grants 10M stock options to insiders and consultants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: 1M units (share + warrant at $0.05) to CEO Clarence Smith for $50,000.","Board increased 2017 Plan reserve from 89.7M to 97.7M shares for future equity awards.","Options for 10M shares granted to CEO, CFO, director, and three consultants at $0.06, vesting quarterly.","Options expire March 14, 2030; total options outstanding now 94,690,000 under the plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385121,"accession_number":"0001079973-22-000154","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["3.03","5.02","5.07","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Stockholders approve increase in authorized shares to 500M; re-elect directors Smith and McDonough","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increase in authorized shares from 400M to 500M approved (184,335,129 for, 1,583,019 against).","Directors re-elected: Clarence Smith (185,055,809 for) and Edward McDonough (183,903,604 for).","Executive compensation plan approved (181,224,448 for; 1,522,342 against; 3,199,261 abstain).","Advisory vote on executive compensation frequency: every three years chosen (175,276,604 for).","Auditor Davidson & Company LLP ratified for FY2022 (195,432,709 for; 1,215,202 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402998,"accession_number":"0001079973-21-001270","cik":1128189,"company_name":"ProtoKinetix, Inc.","ticker":"PKTX","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"ProtoKinetix adopts amended bylaws updating stockholder meeting provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws on December 20, 2021.","Provisions updated to conform to modern practices for stockholder meetings.","Removed requirement to produce list of stockholders entitled to vote; inspection right retained.","Changes intended to provide more flexibility in company governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2252369.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}